Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer

Diseases and Conditions Researched


What is the purpose of this trial?

The primary objective of this study is to determine the progression free survival in patients with metastatic ;pancreatic ;cancer and in patients with locally advanced unresectable non-metastaticpancreatic ;cancer treated with a dose-attenuated modification of folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX). Secondary endpoints include: determine objective response rate according to RECIST; determine overall survival; evaluate toxicity; determine rate of resection in locally advanced unresectable stratum; correlate time to progression, objective response, and overall survival with early changes in glucose metabolism using [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) scanning.


Participation Guidelines

Age: Any
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Yale Cancer Center
Last Updated:
Study HIC#: 1306012255